Sign in
Active, not recruitingPhase 2

Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement

Key facts

Who runs it
Hunter Holmes Mcguire Veteran Affairs Medical Center
Where
Richmond, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
25 people enrolled
Started
2 Nov 2023
Expected to end
1 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Albumin Infusion
Record updated
25 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • Age >18 years
  • Cirrhosis diagnosed using either (a) liver biopsy, (b) transient wave elastography (>20 KPa) (c) radiological evidence consistent with cirrhosis, (d) in a patient with chronic liver disease endoscopic or radiological evidence of varices (e), in a patient with chronic liver disease, platelet count <150,000/mm3 and AST/ALT ratio >1
  • Cognitive impairment defined by MHE on psychometric hepatic encephalopathy score (PHES), critical flicker frequency (CFF), or EncephalApp Stroop
  • Prior HE controlled by lactulose or rifaximin for at least one month
  • Serum albumin <4gm/dl

Who cannot take part

  • No prior overt HE
  • No cognitive impairment on the tests noted
  • Infection within a month
  • Congestive heart failure
  • Requiring regular albumin infusions within 3 months or anticipated during the study visit
  • Allergies to albumin
  • Serum albumin >4gm/dl
  • Unclear diagnosis of cirrhosis
  • Unlikely to be adherent to the study
  • Unable or unwilling to consent
  • West Haven Criteria>2
  • Alcohol abuse within 1 month

Where in United States

  • Hunter Holmes McGuire VA Medical CenterRichmond, United States

About the trial

What the trial wants to find out

Hypothesis: Improvement in cognitive dysfunction with IV albumin in patients with cirrhosis with prior HE and MHE lasts for several weeks after albumin infusion has ended, and is due to persistent improvement in inflammatory markers, endothelial dysfunction, albumin function and gut microbial changes.

Read full original descriptionShow less

This will be a single-arm, single-blind sequential trial of IV 25% albumin and IV saline over 8 weeks with biological sampling and cognitive and health related quality of life (HRQOL) testing with each subject acting as their own control.

The 2 groups in the trial

  • PlaceboPlacebo, for comparison

    Saline given at the same volume as the albumin on visits the patients are assigned to it

    Treatment: Albumin Infusion

  • AlbuminExisting treatment, for comparison

    IV Albumin at 1.5g/kg ideal body weight

    Treatment: Albumin Infusion

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Clinical Trial in Hepatic Encephalopathy to Study Lasting Cognitive Improvement With Intravenous Albumin
Record updated
25 August 2026